Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors

Key Inclusion Criteria: * Participants were aged \>=18 years. * Adequate organ function. * Eastern Cooperative Oncology Group (ECOG) performance status \<=1. * Must have been able to provide a recently obtained archival tumor tissue or fresh tumor biopsy. * The phase 1 dose escalation and phase 2 safety lead-in enrolled participants with histologically/cytologically confirmed advanced/metastatic solid tumors who had previously received standard systemic therapy per local guidelines, unless it was not available, not tolerated or determined not appropriate based on investigators judgement, and had at least 1 evaluable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * The phase 2 dose expansion enrolled participants with recurrent/metastatic HNSCC (Cohorts 1 and 4) and advanced/metastatic NSCLC (Cohorts 2 and 5), with disease progression that occurred \>=10 weeks from the initiation of anti-PD-1/PD-L1 treatment for locally advanced or metastatic disease and had at least 1 measurable lesion outside of the central nervous system per RECIST v1.1. Key Exclusion Criteria: * A history of severe hypersensitivity reactions to other monoclonal antibodies. * Active autoimmune disease or a history of autoimmune diseases that might relapse or a history of life-threatening toxicity related to prior immune therapy. * Any condition that required systemic treatment with either corticosteroids or other immunosuppressive medication \<=14 days before administration of stu…